Netarsudil/latanoprost

Summary of Evidence

Netarsudil/latanoprost FDC vs monotherapy

Netarsudil/latanoprost FDC was superior to either agent alone, lowering IOP by an additional 1.8-3.0 mm Hg vs netarsudil and an additional 1.3-2.5 mm Hg vs latanoprost.(MERCURY-1, 2019) {Asrani S, Robin AL, Serle JB, Lewis RA, Usner DW, Kopczynski CC, Heah T. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial. Am J Ophthalmol. 2019 Nov;207:248-257.}

Netarsudil/latanoprost FDC was superior to either agent alone, lowering IOP by an additional 2.2-3.3 mm Hg vs netarsudil and an additional 1.5-2.4 mm Hg vs latanoprost.(MERCURY-2, 2019) {Walters TR, Ahmed IIK, Lewis RA, Usner DW, Lopez J, Kopczynski CC, Heah T. Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study. Ophthalmol Glaucoma. 2019 Sep – Oct;2(5):280-289.}

Evidence

1. Background

2. Safety and efficacy

2.1 Comparative effectiveness

2.1.1 Netarsudil/latanoprost vs monotherapy

Clinical Trial

2019 Asrani et.al. (MERCURY-1 study)

Article link | Archive link | Metrics

2019
Clinical Trial

Netarsudil/latanoprost FDC was superior to either agent alone, lowering IOP by an additional 1.8-3.0 mm Hg vs netarsudil and an additional 1.3-2.5 mm Hg vs latanoprost {Asrani S, Robin AL, Serle JB, Lewis RA, Usner DW, Kopczynski CC, Heah T. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial. Am J Ophthalmol. 2019 Nov;207:248-257.}

Randomized controlled trial of Netarsudil/Latanoprost Fixed-Dose Combination vs netarsudil 0.02% vs latanoprost 0.005% for up to 12 months (718 patients).
Findings:
- Netarsudil/latanoprost FDC was superior to either agent alone, lowering IOP by an additional 1.8-3.0 mm Hg vs netarsudil and an additional 1.3-2.5 mm Hg vs latanoprost
- At 3 months, the proportion of patients achieving mean diurnal IOP ≤15 mm Hg was 43.5% for netarsudil/latanoprost FDC, 22.7% for netarsudil, and 24.7% for latanoprost.
- The most frequent ocular adverse event was conjunctival hyperemia

	Study	Netarsudil	Latanoprost	Netarsudil/latanoprost FDC
Mean diurnal IOP ≤ 15 mmHg (proportion)	MERCURY-1	15.8%	18.3%	42.1%
	MERCURY-2	22.7%	24.7%	43.5%
Incidence of Conjunctival hyperaemia	MERCURY-1 and 2	41-42.7%	14-22.3%	53.4-54.5%

Asrani et.al. (MERCURY-1 study)
Journal full text Archive Metrics

Clinical Trial

2019 Walters et.al. (MERCURY-2)

Article link | Archive link | Metrics

2019
Clinical Trial

Netarsudil/latanoprost FDC was superior to either agent alone, lowering IOP by an additional 2.2-3.3 mm Hg vs netarsudil and an additional 1.5-2.4 mm Hg vs latanoprost {Walters TR, Ahmed IIK, Lewis RA, Usner DW, Lopez J, Kopczynski CC, Heah T. Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study. Ophthalmol Glaucoma. 2019 Sep – Oct;2(5):280-289.}

Randomized controlled trial of Netarsudil/Latanoprost Fixed-Dose Combination vs netarsudil 0.02% vs latanoprost 0.005% for up to 12 months (750 patients).
Findings:
- Netarsudil/latanoprost FDC was superior to either agent alone, lowering IOP by an additional 2.2-3.3 mm Hg vs netarsudil and an additional 1.5-2.4 mm Hg vs latanoprost
- At 3 months, the proportion of patients achieving mean diurnal IOP ≤15 mm Hg was 42.1% for netarsudil/latanoprost FDC, 15.8% for netarsudil, and 18.3% for latanoprost.

Walters et.al. (MERCURY-2)
Journal full text Archive Metrics

References

Comments

Subscribe

0 Comments

Inline Feedbacks

View all comments